1H-MR spectroscopy in ultra-high risk and first episode stages of schizophrenia

Journal of Psychiatric Research

Volumn 45, Issue 9, 2011, Pages 1135-1139

  Uhl, Idun ^a   Mavrogiorgou, Paraskevi ^a   Norra, Christine ^a   Forstreuter, Frank ^b   Scheel, Michael ^b   Witthaus, Henning ^a   Özgürdal, Seza ^a   Gudlowski, Yehonala ^b   Bohner, Georg ^b   Gallinat, Jürgen ^b   Klingebiel, Randolf ^b   Heinz, Andreas ^b   Juckel, Georg ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Magnetic resonance spectroscopy; Schizophrenia; Ultra high risk

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID; ASPARTIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; N-ACETYLASPARTATE; PROTON;

ADULT; AMINO ACID METABOLISM; ANTERIOR CINGULATE; ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAL PREFRONTAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK ASSESSMENT; SCHIZOPHRENIA; ADOLESCENT; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; CHI SQUARE DISTRIBUTION; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; BRAIN MAPPING; CHI-SQUARE DISTRIBUTION; CHOLINE; CREATINE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 80051668042     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.02.004     Document Type: Article

References (32)

1. Angelie E., Bonmartin A., Boudraa A., Gonnaud P.M., Mallet J.J., Sappey-Marinier D. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. American Journal of Neuroradiology 2001, 22(1):119-127.
2. Assaf M., Rivkin P.R., Kuzu C.H., Calhoun V.D., Kraut M.A., Groth K.M., et al. Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia. Biological Psychiatry 2006, 59:452-459.
3. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry 2001, 49:39-46.
4. Bottlender R., Sato T., Jager M., Wegener U., Wittmann J., Strauss A., et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophrenia Research 2003, 62:37-44.
5. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Henn F.A. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 2001, 34(6):251-253.
6. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Tost H., Henn F.A. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. European Neuropsychopharmacology 2002, 12(2):145-152.
7. Bustillo J.R., Lauriello J., Rowland L.M., Thomson L.M., Petropoulos H., Hammond R., et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophrenia Research 2002, 58:313-321.
8. Dehaene S., Artiges E., Naccache L., Martelli C., Viard A., Schurhoff F., et al. Conscious and subliminal conflicts in normal subjects and patients with schizophrenia: the role of the anterior cingulate. Proceedings of the National Academy of Sciences of the United States 2003, 100:13722-13727.
9. Falkai P., Vogeley K., Maier W. Structural brain changes in patients with schizophrenic psychoses. From focal pathology to network disorder. Nervenarzt 2001, 72:331-341.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV) 1996, American Psychiatric Press, Inc, Washington, D.C.
11. Han X.L., Gross R.W. Proton nuclear magnetic resonance studies on the molecular dynamics of plasmenylcholine/cholesterol and phosphatidylcholine/cholesterol bilayers. Biochimica et Biophysica Acta 1991, 1063:129-136.
12. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berlin) 2004, 174(1):151-162.
13. Jessen F., Scherk H., Traber F., Theyson S., Berning J., Tepest R., et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophrenia Research 2006, 87:81-88.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
15. Kerns J.G., Cohen J.D., MacDonald A.W., Johnson M.K., Stenger V.A., Aizenstein H., et al. Decreased conflict- and error-related activity in the anterior cingulate cortex in subjects with schizophrenia. American Journal of Psychiatry 2005, 162:1833-1839.
16. Keshavan M.S., Dick R.M., Diwadkar V.A., Montrose D.M., Prasad K.M., Stanley J.A. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophrenia Research 2009, 115:88-93.
17. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry 2001, 58:158-164.
18. Lim K.O., Adalsteinsson E., Spielman D., Sullivan E.V., Rosenbloom M.J., Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Archives of General Psychiatry 1998, 55:346-352.
19. Miller T.J., McGlashan T.H., Woods S.W., Stein K., Driesen N., Corcoran C.M., et al. Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly 1999, 70:273-287.
20. Morey R.A., Inan S., Mitchell T.V., Perkins D.O., Lieberman J.A., Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry 2005, 62:254-262.
21. O'Neill J., Levitt J., Caplan R., Asarnow R., McCracken J.T., Toga A.W., et al. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage 2004, 21(4):1781-1789.
22. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
23. Phillips L.J., Velakoulis D., Pantelis C., Wood S., Yuen H.P., Yung A.R., et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophrenia Research 2002, 58:145-158.
24. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 1993, 30:672-679.
25. Ross B., Bluml S. Magnetic resonance spectroscopy of the human brain. Anatomical Record 2001, 265:54-84.
26. Steen R.G., Hamer R.M., Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
27. Theberge J., Al-Semaan Y., Drost D.J., Malla A.K., Neufeld R.W., Bartha R., et al. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Research 2004, 131:107-114.
28. Tsai G., Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology 1995, 46:531-540.
29. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987, 44:660-669.
30. Witthaus H., Kaufmann C., Bohner G., Ozgürdal S., Gudlowski Y., Gallinat J., et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research 2009 Sep 30, 173(3):163-169. Epub 2009 Jul 17.
31. Wood S.J., Berger G., Velakoulis D., Phillips L.J., McGorry P.D., Yung A.R., et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophrenia Bulletin 2003, 29:831-843.
32. Yucel M., Wood S.J., Phillips L.J., Stuart G.W., Smith D.J., Yung A., et al. Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. British Journal of Psychiatry 2003, 182:518-524.